-->
pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-122 |
Genomic Coordinates | chr18: 58451074 - 58451158 |
Synonyms | MIR122A, MIRN122, MIRN122A, hsa-mir-122, miRNA122, miRNA122A, MIR122 |
Description | Homo sapiens miR-122 stem-loop |
Comment | The mature sequence shown here represents the most commonly cloned form from large-scale cloning studies . |
RNA Secondary Structure | |
Associated Diseases |
Mature miRNA Information | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-122-5p | |||||||||||||||||||||
Sequence | 15| UGGAGUGUGACAAUGGUGUUUG |36 | |||||||||||||||||||||
Evidence | Experimental | |||||||||||||||||||||
Experiments | Cloned | |||||||||||||||||||||
Editing Events in miRNAs |
|
|||||||||||||||||||||
SNPs in miRNA |
|
|||||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
miRNAs in Extracellular Vesicles |
Circulating MicroRNA Expression Profiling | Circulating MicroRNA Expression Profiling |
---|
Gene Information | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | SLC7A1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Synonyms | ATRC1, CAT-1, ERR, HCAT1, REC1L | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Description | solute carrier family 7 member 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Transcript | NM_003045 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expression | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Putative miRNA Targets on SLC7A1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
3'UTR of SLC7A1 (miRNA target sites are highlighted) |
>SLC7A1|NM_003045|3'UTR 1 CGCACAGCCCCGCCCCCCGGAGGTGGCAGCAGCCCCGAGGGACGCCCCCAGAGGACCGGGAGGCACCCCACCCTCCCCAC 81 CAGTGCAACAGAAACCACCTGCGTCCACACCCTCACTGCAGCCAAAGGTGCAATTACTTGACCTGCAGCCCCAGCCCACC 161 CTCGGCTCTGCAGCCGGTTCTCCGGGCCCTGGTCACCTCCAGACAGCTGCCTGGCCGGGGCCACTAGGCTGCGGCTGGCC 241 ACTGTGTCTCCTCACTTCTCTGAACAAAGCAGTTCCTCCCCTACCAGCTCAGCCCCGAGCTGCCGCAGCCTCAGGCAGAA 321 CGGAGGTCACCTTCTCTCCTTATCTTGGGAACCAGGCCTTCCTCCCGGGGACTGTTCTGGGATTGAAATTGTGCATACTC 401 CAAACTTTCGCAGCCATCTTCCCGCTCAGCCCCAGACACCCAGCAATCAAGCCAGATGAGTACCACAAAACAGTGTGTCC 481 CCAGCAGCTCCCCACCCCAGAGCCAAATGACAGTAGTGCACTTAAAAAGGAAAATCAGGCCTGTTGTCCTTCTCCGGTTG 561 CATTCAGATGGGTCATTAGGGCCGGACCCTGCCTGCCCCTTGGCTTCTCAGGGCTTTGCTCTGACACCATGACAGCTGCC 641 CGGGGCTGAGGGCAGCTGGCTCCACTCAAATGAGGAAGAAGGGATCACTCCCATTAGGGCCTGCTTTGCTTATGCATGTG 721 TGTGCACATGCATGTAAACCAGGGACCTTCAGCTCACGGCCTCCAGGCCTGGGCCAGTTCTTGCTGCTCCTGCCGTCTCC 801 CCCGACTGGCTGTGTCCTGAGTAACTGGAACATGAGACAGTATCTGCAGGACTGGCCCCATGGTGGCCGAGTCAGAAGTC 881 TGTTTCCTGTGAGTCGCCACCGTTCACTCAGTCTTGCCCTCCCATGCTTTGGAGCCAGTCTGGTGGCTCCTGTAAGGTTC 961 TCAAGGCTGGTGGCAGCTCAGTCTGGGGTCAGGACATGTCGGGGTCATGCGTTTCTGGCCCTGACATAAGCTGTCTGGCC 1041 TCTCTGTGACATGATGAAATTGAAATCAATCCACAGTCCATGAAATTGTGACACTCCACCAGATTAAGTTAGGGCATAAC 1121 ATTAACTTGGAAATGGCCATGTCATCACCCCTGCGGCTGTCCTATAGCTGAGATGCGTGGGTCGCAGGGGAGGTGATTTC 1201 TAGGCATATTGCTGTCCCTTTTGTGTATCTGTCATCCGGATGCTTCGGACCCCACGCCTCTGCAAGTGGGAGAGACCCGA 1281 GCATCCTCCCCACCCCCATAGCTCCAGTGCACGCCACCCCCGTCTTGCCTGGGTCGGGGCCTGCGGCCAGCACCATTTCA 1361 CACACACTCCTTGTAGATGGGAGCCAGAGGAAACCTGAACGTGGGTGGAGCGTTCCACTGAGTCTACTTCAGGAGACAGA 1441 AGGCCCATGCTGATGGGGGAGGAGGAGGGATGTGGGCATTTTGGACACCAGGGGAAATGGAAATGCTGCTTTCAAAACTT 1521 AGTTTCCTTTCCATTTCTTCCTAGTCTGGCCTTTGACACAAATCTGGTAGAAAGAAGCCTGATAAATTGAGGGCACTTGT 1601 ACCCTCCCTGTGCCCCCAGAAGGTTCTTGGAGAGAAGTGCAAGAATTTGTGAACACGGCGGTGGAGGGCGGGTGGATGGC 1681 CATGGGCTGAGCCTCCGTATCAGGCCTGCTCACCTTGCTGGGAGCTTTATTCTGATCTCATTTTGAATGTTCCAGAGGGA 1761 GCATCATAAGAGCCCAGAGCTCCGATTTCCAAAGAGTGATATTGACATTTATGGAGATTGGTGTTGTAACATATTTTGAT 1841 AAATACTAACTTATTTTGTTGGGGTTTTGGTTGTCTCTTGTCTTAGGACCTGGTAGTTATTTGCTTGATTTTTTTTTCCG 1921 TTATTTTCTACATAGGCAAAGAGAATTCGAGGGATAGACAGTCTCCAAGAAAAGTGAAGTGGTGGGAGAGAATTGCTTTT 2001 TTCTTTTTTTTCTTTTCTCTAGTTTTTCTTTCTGGCTGAGATTTCCGTGCAAGACAGCACCCAATAGACTATTTAGAGTT 2081 GACATTTGACATTTTAATGGGCGCCATGGCTCATTTTGTAGATTGAGAAGGTGCGTCTCCCCTGCTCCAAGTCTCATCAT 2161 GACAGCGTGCTGACAGCTGGGAGTCTGTGGCCTTCCTCACGCAGAGGCCTTAAAGCTGGACACAGAAGCACGCCTAGGCT 2241 GGGCAGGGATGGGACCCATGCCCCCTCCTTAGAGGACGGGCTTCCTGGTTAGGAAAGGACACGTGGGGGTGCCTTGCATA 2321 ATAGTTCACTGGTCACCGTGCTTTTATGAGTAGTGTTTTTGTGCACTTGCCAGGGGTTTTCTCTCTGTGTGAGAGGGGAG 2401 TGATTTAAGCAATGGTGTCTGGAGTAAGCCTTACAATTTTAATAGACTTTTTCTTATCATATCCCTCATTTCTTTCCCTG 2481 AAATAAAAATACACACAAGCAAAAAAAAAATGATAGTTTCACATCTCTTAGTTCCCTTGCCCAAACAAGAATATTCTTAG 2561 TTCCACTGGCCAGGATTTTCCTACATAGTCAGAACTTACACATTACTAGAGGCACACCCACCAAGGAGTATTGTGTCTAC 2641 TTTTATCTGTGCACCAGCCACAAATACCCACATTGGAAAGACCCATTTGTGATGGGTAAACATCCCTTCCTGTCTCCCAC 2721 AACCCCTGTGACTGCCCTGCATGTGTTCATGACCTCCGAAGGCCCAAATTCATGAAGCAGCAAACCCAGCAGATCTCCAC 2801 CCCCCTGCCTCAGGACCTCTGCTGAAGAGGGGGATGAAGTGGGTCTCCAGGGAGGCAGTGGGGGCCTTGTTGGCAGCTGG 2881 CTCGGGAGCCGGCTTACAGGAGGGCAGCTCTGCAGTTGGGAGGGGCACCGTCCGGAGGAGACCAGGCCTCTACACACCCC 2961 CCACTCTACTTATCATCCCTGCTCACACACCCTTGTCCAAGGCTTTATGCATCGGATTTATTTTTCCAAATCAAGAGGAC 3041 AGTGATAGATGCATTTTCCCCAGGCTGTCTCAGAAAGGTCGCTAAATGTATACTGTTGTCAGAATTGCTGAGATCTCCCC 3121 CCACTTTTGGTTTTTGCAGCAGTAAAAACTCTTTCCACTGTGACTTATTTTCTCTCTCAGGCAGCCAGCCACCTGGTCCC 3201 TTGTGCTGACTCTAGCACAGTGGCCAGGATCCAATACGAGTCCAGGGGTGACCGCAGGATGGTGGGGGCAGCGGGCTTCT 3281 CCACCTACCCCAGCCACCAAGGCCCTGACGCACTGCCTCCTGCACCTTCAGCACATCCCTGTGCACAGCTGGAAGGGTGC 3361 ATGGCCCGCTCACCTTTGTTCAGATGGGTGGAAACGCTGATGATACCAGCTCCTCCCTGCCGTGCCCCTGCCACGGAGCA 3441 GGCATTGTGAACTGGCTGGTGTTTGCAGTCCCACGTGGCATGGCCTCCAGCCCAACCCACAGTGGAGACTGGAGACAGGG 3521 CAATGAGTCTGGTGGGGGGCACGTGGACATGCCCCATAGGGGCCCCACCCAGACTTAACAGGCAAGGTCCTGGGCATTGC 3601 GCGACGCAGGACTCAATGCTAAAGCAAGCCTGCCTGGCTCTGTGCCAGGGCCCCTCTTCTGATTCACACATCCCATTTTT 3681 ACACAGACCCTTCCTTCTTAATAAAGGCTGACAGTTCTGTTGGCAGCCAAGAACCCACACCATGAAGACAGGGAGTGAGG 3761 GGCCTTTGTGCCCAACTCCAGCACAGCTGCGTTCTGGGGTGTGTGAGAGGCATGTTCGTGTCTGTGCGCTGGTGGTCTCG 3841 TGAGACAGTTCCGAGGACGGGGAAATTGCAGGGTGGTGGGGGCGTGAGGCTTATATGTGGAACTGATGCAGAGTTCGCCT 3921 GCAGACGGATCTGGATATACACTATGTATAATTGTTACGTGTAATTTAAAATATATCTGTTTGCCATCGTCATGAGAAGA 4001 TTATATGTAAGGCTCTGAAGGGAGAGGGAGATGTACATTCTGCCAGGCTCCTGGGGACCTTATCCGAGTCATGAAATTGA 4081 TTACTGTTGATCCAGTGGTGCAAGAAGCTACACTCCATGTGTCATCACGCTTATGACTCCTAATGTATTTTTAAGGCAAA 4161 AAATGTCAGCCGACTCCATCTTCACCCCTCGATTCCTCGAGTCCAGCCTTTCTGTGCCAGTGCTTCACTGAGCCACAACG 4241 CTCTCGCCATCGGGACCCGGCTGGGCCTGGAGTCTCGGGGCACAGTTGCCATGGAGCCCTCCTGGGTCATTCTACAAATG 4321 TGCTGAGTGCCAGCTGAAAACCCCACAGGAGATGGAGTACCTTGGCCAAGCTTAAAGAGAAGATTTTCTCAGGGTATTTA 4401 TTAGTGTGTCCAGCAGGGTCAGGAAGCAGGATGGAAAGATGCACTCAGACTGTTAATTTATTAACAAGGCAAATGATTTT 4481 GTGTTTCTTGATGACAGACTATTAAGTTTGGGACTTATTTTCCCATTTGAGAAGTTATAATATATATTTAAGATGATAAG 4561 TTTCCTGCTTAAGTTGTGCCTTTCAGCTTCAATGAGTTTAAGGAGCACTAAGGGTAATGATACCAATGAGGGTTGGTTTA 4641 TTATCAAACCTGAATAGCTGTGGTTTCTCCAGTAAATATTTTCTTCTACTGAACATGGAGCCATTATTAAGAGTTGTGTG 4721 TTTTTTATTATGTACATTTGTATATTTTTTTGCTTGTTTGATGTTCTATTTTTCTAATAGTTTTCTTTTAGTTTCTTAAA 4801 GTTGTGATACTAGATTTAGATTCTGATGCTAACTGCAAATCAGGTTGGTCTCTGCTGGGTCTCTCCTGCTTTTATTTTAC 4881 TTTAAGGACAAGTGTAGTTGTCGTCCACCACCTTTCAAAAAATGTGAAACTGCCCTGCCTCCCCTTTTTGCTGACAACAC 4961 TGTGTACATTGACCACTTCCTACCATACTTTATGTTGTAAAATCAAACTCTTTTGTGGTACATTATCTCATGCTTCTGCA 5041 AATTCGAATAAATTCTATGGCTTCCAAAAAAAAAAAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
DRVs in gene 3'UTRs |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SNPs in gene 3'UTRs |
|
Experimental Support 1 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | Huh7 |
Location of target site | 3'UTR |
Original Description (Extracted from the article) |
...
"Reporter activity
... - Bhattacharyya SN; Habermacher R; Martine U; et al., 2006, Cell. |
Article |
- Bhattacharyya SN; Habermacher R; Martine U; et al. - Cell, 2006
In metazoans, most microRNAs imperfectly base-pair with the 3' untranslated region (3'UTR) of target mRNAs and prevent protein accumulation by either repressing translation or inducing mRNA degradation. Examples of specific mRNAs undergoing microRNA-mediated repression are numerous, but whether the repression is a reversible process remains largely unknown. Here we show that cationic amino acid transporter 1 (CAT-1) mRNA and reporters bearing its 3'UTR can be relieved from the microRNA miR-122-induced inhibition in human hepatocarcinoma cells subjected to different stress conditions. The derepression of CAT-1 mRNA is accompanied by its release from cytoplasmic processing bodies and its recruitment to polysomes. The derepression requires binding of HuR, an AU-rich-element binding protein, to the 3'UTR of CAT-1 mRNA. We propose that proteins interacting with the 3'UTR will generally act as modifiers altering the potential of miRNAs to repress gene expression.
LinkOut: [PMID: 16777601]
|
Experimental Support 2 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | Huh7 , HepG2 , 293T , AML-12 , WC-3 |
Location of target site | 3'UTR |
Tools used in this research | miRanda |
Article |
- Chang J; Nicolas E; Marks D; Sander C; et al. - RNA biology, 2004
These studies show that miR-122, a 22-nucleotide microRNA, is derived from a liver-specific noncoding polyadenylated RNA transcribed from the gene hcr. The exact sequence of miR-122 as well as the adjacent secondary structure within the hcr mRNA are conserved from mammalian species back to fish. Levels of miR-122 in the mouse liver increase to half maximal values around day 17 of embryogenesis, and reach near maximal levels of 50,000 copies per average cell before birth. Lewis et al. (2003) predicted the cationic amino acid transporter (CAT-1 or SLC7A1) as a miR-122 target. CAT-1 protein and its mRNA are expressed in all mammalian tissues but with lower levels in adult liver. Furthermore, during mouse liver development CAT-1 mRNA decreases in an almost inverse correlation with miR-122. Eight potential miR-122 target sites were predicted within the human CAT-1 mRNA, with six in the 3'-untranslated region. Using a reporter construct it was found that just three of the predicted sites, linked in a 400-nucleotide sequence from human CAT-1, acted with synergy and were sufficient to strongly inhibit protein synthesis and reduce mRNA levels. In summary, these studies followed the accumulation during development of miR-122 from its mRNA precursor, hcr, through to identification of what may be a specific mRNA target, CAT-1.
LinkOut: [PMID: 17179747]
|
Experimental Support 3 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Location of target site | 3'UTR |
Original Description (Extracted from the article) |
...
"Our results show that all three predicted regulated genes in humans(and pre-validated in mouse [Esau et al. 2006])
... - Fabani MM; Gait MJ, 2008, RNA (New York, N.Y.). |
Article |
- Fabani MM; Gait MJ - RNA (New York, N.Y.), 2008
MicroRNAs are small noncoding RNAs that regulate many cellular processes in a post-transcriptional mode. MicroRNA knockdown by antisense oligonucleotides is a useful strategy to explore microRNA functionality and as potential therapeutics. MicroRNA-122 (miR-122) is a liver-specific microRNA, the main function of which has been linked with lipid metabolism and liver homeostasis. Here, we show that lipofection of an antisense oligonucleotide based on a Locked Nucleic Acids (LNA)/2'-O-methyl mixmer or electroporation of a Peptide Nucleic Acid (PNA) oligomer is effective at blocking miR-122 activity in human and rat liver cells. These oligonucleotide analogs, evaluated for the first time in microRNA inhibition, are more effective than standard 2'-O-methyl oligonucleotides in binding and inhibiting microRNA action. We also show that microRNA inhibition can be achieved without the need for transfection or electroporation of the human or rat cell lines, by conjugation of an antisense PNA to the cell-penetrating peptide R6-Penetratin, or merely by linkage to just four Lys residues, highlighting the potential of PNA for future therapeutic applications as well as for studying microRNA function.
LinkOut: [PMID: 18073344]
|
Experimental Support 4 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | HEK293T |
Location of target site | 3'UTR |
Tools used in this research | miRanda |
Original Description (Extracted from the article) |
...
Verification of miR-122 target genes using 3'UTR reporter assay is shown in Supporting Table 4.
... - Tsai WC; Hsu PW; Lai TC; Chau GY; Lin CW; et al., 2009, Hepatology (Baltimore, Md.). |
Article |
- Tsai WC; Hsu PW; Lai TC; Chau GY; Lin CW; et al. - Hepatology (Baltimore, Md.), 2009
UNLABELLED: MicroRNAs (miRNAs), which are inhibitors of gene expression, participate in diverse biological functions and in carcinogenesis. In this study, we show that liver-specific microRNA-122 (miR-122) is significantly down-regulated in liver cancers with intrahepatic metastasis and negatively regulates tumorigenesis. Restoration of miR-122 in metastatic Mahlavu and SK-HEP-1 cells significantly reduced in vitro migration, invasion, and anchorage-independent growth as well as in vivo tumorigenesis, angiogenesis, and intrahepatic metastasis in an orthotopic liver cancer model. Because an inverse expression pattern is often present between an miRNA and its target genes, we used a computational approach and identified multiple miR-122 candidate target genes from two independent expression microarray datasets. Thirty-two target genes were empirically verified, and this group of genes was enriched with genes regulating cell movement, cell morphology, cell-cell signaling, and transcription. We further showed that one of the miR-122 targets, ADAM17 (a disintegrin and metalloprotease 17) is involved in metastasis. Silencing of ADAM17 resulted in a dramatic reduction of in vitro migration, invasion, in vivo tumorigenesis, angiogenesis, and local invasion in the livers of nude mice, which is similar to that which occurs with the restoration of miR-122. CONCLUSION: Our study suggests that miR-122, a tumor suppressor microRNA affecting hepatocellular carcinoma intrahepatic metastasis by angiogenesis suppression, exerts some of its action via regulation of ADAM17. Restoration of miR-122 has a far-reaching effect on the cell. Using the concomitant down-regulation of its targets, including ADAM17, a rational therapeutic strategy based on miR-122 may prove to be beneficial for patients with hepatocellular carcinoma.
LinkOut: [PMID: 19296470]
|
MiRNA-Target Expression Profile | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT000012 | CYP7A1 | cytochrome P450 family 7 subfamily A member 1 | 3 | 1 | ||||||||
MIRT000364 | IGF1R | insulin like growth factor 1 receptor | 4 | 3 | ||||||||
MIRT000365 | SRF | serum response factor | 4 | 1 | ||||||||
MIRT000663 | RAC1 | Rac family small GTPase 1 | 5 | 2 | ||||||||
MIRT000717 | RHOA | ras homolog family member A | 2 | 2 | ||||||||
MIRT003006 | CCNG1 | cyclin G1 | 4 | 4 | ||||||||
MIRT003079 | GTF2B | general transcription factor IIB | 2 | 1 | ||||||||
MIRT003080 | GYS1 | glycogen synthase 1 | 4 | 2 | ||||||||
MIRT003081 | ANK2 | ankyrin 2 | 3 | 1 | ||||||||
MIRT003082 | NFATC2IP | nuclear factor of activated T-cells 2 interacting protein | 3 | 1 | ||||||||
MIRT003083 | ENTPD4 | ectonucleoside triphosphate diphosphohydrolase 4 | 4 | 2 | ||||||||
MIRT003084 | ANXA11 | annexin A11 | 4 | 2 | ||||||||
MIRT003085 | ALDOA | aldolase, fructose-bisphosphate A | 3 | 2 | ||||||||
MIRT003086 | RAB6B | RAB6B, member RAS oncogene family | 3 | 1 | ||||||||
MIRT003087 | RAB11FIP1 | RAB11 family interacting protein 1 | 5 | 3 | ||||||||
MIRT003088 | FOXP1 | forkhead box P1 | 3 | 1 | ||||||||
MIRT003089 | MECP2 | methyl-CpG binding protein 2 | 3 | 2 | ||||||||
MIRT003090 | NCAM1 | neural cell adhesion molecule 1 | 4 | 3 | ||||||||
MIRT003091 | UBAP2 | ubiquitin associated protein 2 | 3 | 1 | ||||||||
MIRT003092 | TBX19 | T-box 19 | 3 | 1 | ||||||||
MIRT003093 | AACS | acetoacetyl-CoA synthetase | 3 | 1 | ||||||||
MIRT003094 | DUSP2 | dual specificity phosphatase 2 | 3 | 1 | ||||||||
MIRT003095 | ATP1A2 | ATPase Na+/K+ transporting subunit alpha 2 | 3 | 1 | ||||||||
MIRT003097 | MAPK11 | mitogen-activated protein kinase 11 | 3 | 1 | ||||||||
MIRT003098 | FUNDC2 | FUN14 domain containing 2 | 3 | 1 | ||||||||
MIRT003099 | AKT3 | AKT serine/threonine kinase 3 | 3 | 3 | ||||||||
MIRT003100 | TPD52L2 | tumor protein D52 like 2 | 4 | 3 | ||||||||
MIRT003102 | GALNT10 | polypeptide N-acetylgalactosaminyltransferase 10 | 4 | 2 | ||||||||
MIRT003103 | G6PC3 | glucose-6-phosphatase catalytic subunit 3 | 4 | 2 | ||||||||
MIRT003104 | AP3M2 | adaptor related protein complex 3 mu 2 subunit | 3 | 1 | ||||||||
MIRT003105 | SLC7A1 | solute carrier family 7 member 1 | 4 | 4 | ||||||||
MIRT003106 | XPO6 | exportin 6 | 3 | 1 | ||||||||
MIRT003107 | FOXJ3 | forkhead box J3 | 3 | 1 | ||||||||
MIRT003108 | SLC7A11 | solute carrier family 7 member 11 | 3 | 1 | ||||||||
MIRT003109 | TRIB1 | tribbles pseudokinase 1 | 3 | 1 | ||||||||
MIRT003110 | EGLN3 | egl-9 family hypoxia inducible factor 3 | 3 | 1 | ||||||||
MIRT003111 | NUMBL | NUMB like, endocytic adaptor protein | 3 | 1 | ||||||||
MIRT003112 | ADAM17 | ADAM metallopeptidase domain 17 | 3 | 5 | ||||||||
MIRT003727 | DSTYK | dual serine/threonine and tyrosine protein kinase | 3 | 2 | ||||||||
MIRT003728 | FAM117B | family with sequence similarity 117 member B | 3 | 1 | ||||||||
MIRT004364 | BCL2L2 | BCL2 like 2 | 4 | 2 | ||||||||
MIRT004527 | PRKAB1 | protein kinase AMP-activated non-catalytic subunit beta 1 | 2 | 1 | ||||||||
MIRT004879 | ADAM10 | ADAM metallopeptidase domain 10 | 5 | 1 | ||||||||
MIRT005782 | ACVR1C | activin A receptor type 1C | 1 | 1 | ||||||||
MIRT006123 | PRKRA | protein activator of interferon induced protein kinase EIF2AK2 | 4 | 1 | ||||||||
MIRT006421 | WNT1 | Wnt family member 1 | 3 | 1 | ||||||||
MIRT007007 | PTPN1 | protein tyrosine phosphatase, non-receptor type 1 | 1 | 1 | ||||||||
MIRT007081 | NT5C3A | 5'-nucleotidase, cytosolic IIIA | 1 | 1 | ||||||||
MIRT007082 | P4HA1 | prolyl 4-hydroxylase subunit alpha 1 | 1 | 1 | ||||||||
MIRT007083 | ZNF395 | zinc finger protein 395 | 1 | 1 | ||||||||
MIRT007084 | SOCS1 | suppressor of cytokine signaling 1 | 1 | 1 | ||||||||
MIRT023217 | SSR3 | signal sequence receptor subunit 3 | 1 | 1 | ||||||||
MIRT023218 | PHOX2A | paired like homeobox 2a | 1 | 1 | ||||||||
MIRT023219 | DZIP1L | DAZ interacting zinc finger protein 1 like | 1 | 1 | ||||||||
MIRT023220 | GSTM2 | glutathione S-transferase mu 2 | 1 | 1 | ||||||||
MIRT023221 | RAI14 | retinoic acid induced 14 | 1 | 1 | ||||||||
MIRT023222 | STARD13 | StAR related lipid transfer domain containing 13 | 1 | 1 | ||||||||
MIRT023223 | CNN3 | calponin 3 | 1 | 1 | ||||||||
MIRT023224 | A2M | alpha-2-macroglobulin | 1 | 1 | ||||||||
MIRT023225 | EFCAB6 | EF-hand calcium binding domain 6 | 1 | 1 | ||||||||
MIRT023226 | GLOD4 | glyoxalase domain containing 4 | 1 | 1 | ||||||||
MIRT023227 | CALR | calreticulin | 1 | 1 | ||||||||
MIRT023228 | POFUT1 | protein O-fucosyltransferase 1 | 1 | 1 | ||||||||
MIRT023229 | PYGO1 | pygopus family PHD finger 1 | 1 | 1 | ||||||||
MIRT023230 | CDY2B | chromodomain Y-linked 2B | 1 | 1 | ||||||||
MIRT023231 | CDC42EP3 | CDC42 effector protein 3 | 1 | 1 | ||||||||
MIRT023232 | CS | citrate synthase | 3 | 3 | ||||||||
MIRT023233 | RNF170 | ring finger protein 170 | 3 | 3 | ||||||||
MIRT023234 | GTF3C6 | general transcription factor IIIC subunit 6 | 1 | 1 | ||||||||
MIRT023235 | ZNF321P | zinc finger protein 321, pseudogene | 1 | 1 | ||||||||
MIRT023236 | LAMP1 | lysosomal associated membrane protein 1 | 1 | 1 | ||||||||
MIRT023237 | SLC52A2 | solute carrier family 52 member 2 | 1 | 1 | ||||||||
MIRT023238 | ZNF658 | zinc finger protein 658 | 1 | 1 | ||||||||
MIRT023239 | ATP13A3 | ATPase 13A3 | 1 | 1 | ||||||||
MIRT023240 | CPNE5 | copine 5 | 1 | 1 | ||||||||
MIRT023241 | KATNAL1 | katanin catalytic subunit A1 like 1 | 1 | 1 | ||||||||
MIRT023242 | TMEM136 | transmembrane protein 136 | 1 | 1 | ||||||||
MIRT023243 | ATP11A | ATPase phospholipid transporting 11A | 1 | 1 | ||||||||
MIRT023244 | TMEM74 | transmembrane protein 74 | 1 | 1 | ||||||||
MIRT023245 | ANKRD10 | ankyrin repeat domain 10 | 1 | 1 | ||||||||
MIRT023246 | TBL1XR1 | transducin beta like 1 X-linked receptor 1 | 1 | 1 | ||||||||
MIRT023247 | USP10 | ubiquitin specific peptidase 10 | 1 | 1 | ||||||||
MIRT023248 | AKAP11 | A-kinase anchoring protein 11 | 1 | 1 | ||||||||
MIRT023249 | BACH2 | BTB domain and CNC homolog 2 | 1 | 1 | ||||||||
MIRT023250 | HCCS | holocytochrome c synthase | 1 | 1 | ||||||||
MIRT023251 | Slc7a1 | solute carrier family 7 (cationic amino acid transporter, y+ system), member 1 | 1 | 1 | ||||||||
MIRT023252 | GTDC2 | protein O-linked mannose N-acetylglucosaminyltransferase 2 (beta 1,4-) | 1 | 1 | ||||||||
MIRT023253 | CTPS1 | CTP synthase 1 | 1 | 1 | ||||||||
MIRT023254 | SLC44A1 | solute carrier family 44 member 1 | 1 | 1 | ||||||||
MIRT023255 | CLSPN | claspin | 1 | 1 | ||||||||
MIRT023256 | RABGEF1 | RAB guanine nucleotide exchange factor 1 | 1 | 1 | ||||||||
MIRT023257 | FBXO7 | F-box protein 7 | 1 | 1 | ||||||||
MIRT023258 | NCDN | neurochondrin | 1 | 1 | ||||||||
MIRT023259 | SOX2 | SRY-box 2 | 1 | 1 | ||||||||
MIRT023260 | ZNF618 | zinc finger protein 618 | 1 | 1 | ||||||||
MIRT023261 | ABLIM1 | actin binding LIM protein 1 | 1 | 1 | ||||||||
MIRT023262 | ZBTB4 | zinc finger and BTB domain containing 4 | 1 | 1 | ||||||||
MIRT023263 | LUZP1 | leucine zipper protein 1 | 1 | 1 | ||||||||
MIRT023264 | NLGN3 | neuroligin 3 | 1 | 1 | ||||||||
MIRT023265 | PRR11 | proline rich 11 | 1 | 1 | ||||||||
MIRT023266 | HHAT | hedgehog acyltransferase | 1 | 1 | ||||||||
MIRT023267 | UBE2L3 | ubiquitin conjugating enzyme E2 L3 | 1 | 1 | ||||||||
MIRT023268 | DNAJC18 | DnaJ heat shock protein family (Hsp40) member C18 | 1 | 1 | ||||||||
MIRT023269 | FAM102A | family with sequence similarity 102 member A | 1 | 1 | ||||||||
MIRT023270 | PFKFB2 | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 | 1 | 1 | ||||||||
MIRT023271 | DENND2C | DENN domain containing 2C | 1 | 1 | ||||||||
MIRT023272 | HMOX1 | heme oxygenase 1 | 3 | 2 | ||||||||
MIRT023273 | USP28 | ubiquitin specific peptidase 28 | 1 | 1 | ||||||||
MIRT023274 | KRT18 | keratin 18 | 1 | 1 | ||||||||
MIRT023275 | BPGM | bisphosphoglycerate mutase | 1 | 1 | ||||||||
MIRT023276 | ZNF233 | zinc finger protein 233 | 1 | 1 | ||||||||
MIRT023277 | SLC25A30 | solute carrier family 25 member 30 | 1 | 1 | ||||||||
MIRT023278 | ANKRD9 | ankyrin repeat domain 9 | 3 | 3 | ||||||||
MIRT023279 | RLN1 | relaxin 1 | 1 | 1 | ||||||||
MIRT023280 | DDIT3 | DNA damage inducible transcript 3 | 1 | 1 | ||||||||
MIRT023281 | TRIM65 | tripartite motif containing 65 | 1 | 1 | ||||||||
MIRT023282 | B4GALT1 | beta-1,4-galactosyltransferase 1 | 1 | 1 | ||||||||
MIRT023283 | ANXA7 | annexin A7 | 1 | 1 | ||||||||
MIRT023284 | SLC19A2 | solute carrier family 19 member 2 | 1 | 1 | ||||||||
MIRT023285 | MARCKS | myristoylated alanine rich protein kinase C substrate | 1 | 1 | ||||||||
MIRT023286 | CLEC11A | C-type lectin domain containing 11A | 1 | 1 | ||||||||
MIRT023287 | CENPF | centromere protein F | 1 | 1 | ||||||||
MIRT023288 | CLDN18 | claudin 18 | 1 | 1 | ||||||||
MIRT023289 | PFDN1 | prefoldin subunit 1 | 1 | 1 | ||||||||
MIRT023290 | SPAG9 | sperm associated antigen 9 | 1 | 1 | ||||||||
MIRT023291 | CEACAM8 | carcinoembryonic antigen related cell adhesion molecule 8 | 1 | 1 | ||||||||
MIRT023292 | KRT10 | keratin 10 | 1 | 1 | ||||||||
MIRT023293 | SET | SET nuclear proto-oncogene | 1 | 1 | ||||||||
MIRT023294 | SLC11A2 | solute carrier family 11 member 2 | 1 | 1 | ||||||||
MIRT023295 | MYCBP | MYC binding protein | 3 | 3 | ||||||||
MIRT023296 | GPHB5 | glycoprotein hormone beta 5 | 1 | 1 | ||||||||
MIRT023297 | STAU2 | staufen double-stranded RNA binding protein 2 | 1 | 1 | ||||||||
MIRT023298 | NFATC1 | nuclear factor of activated T-cells 1 | 1 | 1 | ||||||||
MIRT023299 | ERP29 | endoplasmic reticulum protein 29 | 1 | 1 | ||||||||
MIRT023300 | MEP1A | meprin A subunit alpha | 1 | 1 | ||||||||
MIRT023301 | SPTLC1 | serine palmitoyltransferase long chain base subunit 1 | 1 | 1 | ||||||||
MIRT023302 | GTF2H2 | general transcription factor IIH subunit 2 | 1 | 1 | ||||||||
MIRT023303 | C14orf39 | chromosome 14 open reading frame 39 | 1 | 1 | ||||||||
MIRT023304 | UBE2K | ubiquitin conjugating enzyme E2 K | 1 | 1 | ||||||||
MIRT023305 | PPP1R9B | protein phosphatase 1 regulatory subunit 9B | 1 | 1 | ||||||||
MIRT023306 | PSMD10 | proteasome 26S subunit, non-ATPase 10 | 1 | 1 | ||||||||
MIRT023307 | CALD1 | caldesmon 1 | 1 | 1 | ||||||||
MIRT023308 | TTYH3 | tweety family member 3 | 1 | 1 | ||||||||
MIRT023309 | NMNAT2 | nicotinamide nucleotide adenylyltransferase 2 | 1 | 1 | ||||||||
MIRT023310 | SCN4B | sodium voltage-gated channel beta subunit 4 | 1 | 1 | ||||||||
MIRT023311 | C1orf122 | chromosome 1 open reading frame 122 | 1 | 1 | ||||||||
MIRT023312 | PAK1 | p21 (RAC1) activated kinase 1 | 1 | 1 | ||||||||
MIRT023313 | DNAJB1 | DnaJ heat shock protein family (Hsp40) member B1 | 1 | 1 | ||||||||
MIRT023314 | DMXL1 | Dmx like 1 | 1 | 1 | ||||||||
MIRT023315 | ZNF160 | zinc finger protein 160 | 1 | 1 | ||||||||
MIRT023316 | CSRP1 | cysteine and glycine rich protein 1 | 1 | 1 | ||||||||
MIRT023317 | PHKA1 | phosphorylase kinase regulatory subunit alpha 1 | 1 | 1 | ||||||||
MIRT023318 | RBBP5 | RB binding protein 5, histone lysine methyltransferase complex subunit | 1 | 1 | ||||||||
MIRT023319 | ANKRD13C | ankyrin repeat domain 13C | 1 | 1 | ||||||||
MIRT023320 | SUCLA2 | succinate-CoA ligase ADP-forming beta subunit | 1 | 1 | ||||||||
MIRT023321 | PEA15 | phosphoprotein enriched in astrocytes 15 | 1 | 1 | ||||||||
MIRT023322 | MTPN | myotrophin | 1 | 1 | ||||||||
MIRT023323 | YKT6 | YKT6 v-SNARE homolog | 1 | 1 | ||||||||
MIRT023324 | MOB3B | MOB kinase activator 3B | 1 | 1 | ||||||||
MIRT023325 | FAM118A | family with sequence similarity 118 member A | 1 | 1 | ||||||||
MIRT023326 | ZNF264 | zinc finger protein 264 | 1 | 1 | ||||||||
MIRT023327 | HECTD3 | HECT domain E3 ubiquitin protein ligase 3 | 1 | 1 | ||||||||
MIRT023328 | BATF2 | basic leucine zipper ATF-like transcription factor 2 | 1 | 1 | ||||||||
MIRT023329 | PIP4K2A | phosphatidylinositol-5-phosphate 4-kinase type 2 alpha | 1 | 1 | ||||||||
MIRT023330 | MAPRE1 | microtubule associated protein RP/EB family member 1 | 1 | 1 | ||||||||
MIRT023331 | TBC1D22B | TBC1 domain family member 22B | 1 | 1 | ||||||||
MIRT023332 | SLC9A1 | solute carrier family 9 member A1 | 3 | 3 | ||||||||
MIRT023333 | NPEPPS | aminopeptidase puromycin sensitive | 1 | 1 | ||||||||
MIRT023334 | BCL2L1 | BCL2 like 1 | 2 | 1 | ||||||||
MIRT023335 | OSMR | oncostatin M receptor | 1 | 1 | ||||||||
MIRT023336 | CALU | calumenin | 1 | 1 | ||||||||
MIRT023337 | BRI3BP | BRI3 binding protein | 1 | 1 | ||||||||
MIRT023338 | PSPH | phosphoserine phosphatase | 1 | 1 | ||||||||
MIRT023339 | APMAP | adipocyte plasma membrane associated protein | 1 | 1 | ||||||||
MIRT023340 | WASF1 | WAS protein family member 1 | 1 | 1 | ||||||||
MIRT023341 | LCA5 | LCA5, lebercilin | 1 | 1 | ||||||||
MIRT023342 | NODAL | nodal growth differentiation factor | 1 | 1 | ||||||||
MIRT023343 | CASP7 | caspase 7 | 1 | 1 | ||||||||
MIRT023344 | CPA3 | carboxypeptidase A3 | 1 | 1 | ||||||||
MIRT023345 | PALM | paralemmin | 1 | 1 | ||||||||
MIRT023346 | TCP11 | t-complex 11 | 1 | 1 | ||||||||
MIRT023347 | NALCN | sodium leak channel, non-selective | 1 | 1 | ||||||||
MIRT023348 | PLAGL2 | PLAG1 like zinc finger 2 | 1 | 1 | ||||||||
MIRT023349 | IDS | iduronate 2-sulfatase | 3 | 3 | ||||||||
MIRT023350 | PARP11 | poly(ADP-ribose) polymerase family member 11 | 1 | 1 | ||||||||
MIRT023351 | MAZ | MYC associated zinc finger protein | 1 | 1 | ||||||||
MIRT023352 | CPNE4 | copine 4 | 1 | 1 | ||||||||
MIRT023353 | FAM19A3 | family with sequence similarity 19 member A3, C-C motif chemokine like | 1 | 1 | ||||||||
MIRT023354 | KRT14 | keratin 14 | 1 | 1 | ||||||||
MIRT023355 | DYNC1H1 | dynein cytoplasmic 1 heavy chain 1 | 1 | 1 | ||||||||
MIRT023356 | GNL3L | G protein nucleolar 3 like | 1 | 1 | ||||||||
MIRT023357 | HLA-DQA1 | major histocompatibility complex, class II, DQ alpha 1 | 1 | 1 | ||||||||
MIRT023358 | EYA4 | EYA transcriptional coactivator and phosphatase 4 | 1 | 1 | ||||||||
MIRT023359 | GNPDA2 | glucosamine-6-phosphate deaminase 2 | 1 | 1 | ||||||||
MIRT023360 | BRCA2 | BRCA2, DNA repair associated | 1 | 1 | ||||||||
MIRT023361 | ZSCAN4 | zinc finger and SCAN domain containing 4 | 1 | 1 | ||||||||
MIRT023362 | HSPA5 | heat shock protein family A (Hsp70) member 5 | 1 | 1 | ||||||||
MIRT023363 | SERAC1 | serine active site containing 1 | 1 | 1 | ||||||||
MIRT023364 | SLC15A2 | solute carrier family 15 member 2 | 1 | 1 | ||||||||
MIRT023365 | RABIF | RAB interacting factor | 1 | 1 | ||||||||
MIRT023366 | ART3 | ADP-ribosyltransferase 3 | 1 | 1 | ||||||||
MIRT023367 | EP400 | E1A binding protein p400 | 1 | 1 | ||||||||
MIRT023368 | MT4 | metallothionein 4 | 1 | 1 | ||||||||
MIRT023369 | TRAM2 | translocation associated membrane protein 2 | 1 | 1 | ||||||||
MIRT023370 | PHPT1 | phosphohistidine phosphatase 1 | 1 | 1 | ||||||||
MIRT023371 | KIAA0101 | PCNA clamp associated factor | 1 | 1 | ||||||||
MIRT023372 | VHL | von Hippel-Lindau tumor suppressor | 1 | 1 | ||||||||
MIRT023373 | IFNA1 | interferon alpha 1 | 1 | 1 | ||||||||
MIRT023374 | FSTL3 | follistatin like 3 | 1 | 1 | ||||||||
MIRT023375 | PHF14 | PHD finger protein 14 | 1 | 1 | ||||||||
MIRT023376 | ZCCHC2 | zinc finger CCHC-type containing 2 | 1 | 1 | ||||||||
MIRT023377 | GSTM3 | glutathione S-transferase mu 3 | 1 | 1 | ||||||||
MIRT023378 | DCTN5 | dynactin subunit 5 | 1 | 1 | ||||||||
MIRT023379 | CHST3 | carbohydrate sulfotransferase 3 | 1 | 1 | ||||||||
MIRT023380 | HECW2 | HECT, C2 and WW domain containing E3 ubiquitin protein ligase 2 | 1 | 1 | ||||||||
MIRT023381 | ADO | 2-aminoethanethiol dioxygenase | 1 | 1 | ||||||||
MIRT023382 | POMZP3 | POM121 and ZP3 fusion | 1 | 1 | ||||||||
MIRT023383 | CHST12 | carbohydrate sulfotransferase 12 | 1 | 1 | ||||||||
MIRT023384 | ARSB | arylsulfatase B | 1 | 1 | ||||||||
MIRT023385 | ATP7A | ATPase copper transporting alpha | 1 | 1 | ||||||||
MIRT023386 | PMP22 | peripheral myelin protein 22 | 1 | 1 | ||||||||
MIRT023387 | TGFBRAP1 | transforming growth factor beta receptor associated protein 1 | 1 | 1 | ||||||||
MIRT023388 | ORC2 | origin recognition complex subunit 2 | 1 | 1 | ||||||||
MIRT023389 | CREB1 | cAMP responsive element binding protein 1 | 1 | 1 | ||||||||
MIRT023390 | CD83 | CD83 molecule | 1 | 1 | ||||||||
MIRT023391 | TOB2 | transducer of ERBB2, 2 | 3 | 5 | ||||||||
MIRT023392 | LRP11 | LDL receptor related protein 11 | 1 | 1 | ||||||||
MIRT023393 | MPV17 | MPV17, mitochondrial inner membrane protein | 1 | 1 | ||||||||
MIRT023394 | TRIM29 | tripartite motif containing 29 | 1 | 1 | ||||||||
MIRT023395 | OSBP2 | oxysterol binding protein 2 | 1 | 1 | ||||||||
MIRT023396 | PKM | pyruvate kinase, muscle | 6 | 4 | ||||||||
MIRT023397 | FOXK2 | forkhead box K2 | 3 | 3 | ||||||||
MIRT023398 | CLIC4 | chloride intracellular channel 4 | 5 | 6 | ||||||||
MIRT023399 | ST6GALNAC4 | ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 4 | 1 | 1 | ||||||||
MIRT023400 | SMURF2 | SMAD specific E3 ubiquitin protein ligase 2 | 1 | 1 | ||||||||
MIRT023401 | LMNB2 | lamin B2 | 3 | 5 | ||||||||
MIRT023402 | BAX | BCL2 associated X, apoptosis regulator | 2 | 2 | ||||||||
MIRT023403 | CDK4 | cyclin dependent kinase 4 | 3 | 3 | ||||||||
MIRT054362 | Cux1 | cut-like homeobox 1 | 1 | 1 | ||||||||
MIRT074336 | TNRC6A | trinucleotide repeat containing 6A | 2 | 2 | ||||||||
MIRT109185 | VMA21 | VMA21, vacuolar ATPase assembly factor | 2 | 4 | ||||||||
MIRT324745 | ACER2 | alkaline ceramidase 2 | 2 | 2 | ||||||||
MIRT325564 | HIATL1 | major facilitator superfamily domain containing 14B | 2 | 4 | ||||||||
MIRT438005 | MEF2D | myocyte enhancer factor 2D | 1 | 2 | ||||||||
MIRT438206 | TGFB1 | transforming growth factor beta 1 | 1 | 1 | ||||||||
MIRT438639 | AXL | AXL receptor tyrosine kinase | 1 | 1 | ||||||||
MIRT438655 | NOD2 | nucleotide binding oligomerization domain containing 2 | 3 | 1 | ||||||||
MIRT438734 | FUT8 | fucosyltransferase 8 | 3 | 1 | ||||||||
MIRT449879 | CYP3A5 | cytochrome P450 family 3 subfamily A member 5 | 2 | 2 | ||||||||
MIRT451716 | OLR1 | oxidized low density lipoprotein receptor 1 | 2 | 2 | ||||||||
MIRT453274 | EFTUD2 | elongation factor Tu GTP binding domain containing 2 | 2 | 2 | ||||||||
MIRT454113 | MRPL52 | mitochondrial ribosomal protein L52 | 2 | 2 | ||||||||
MIRT454232 | OSBPL10 | oxysterol binding protein like 10 | 2 | 15 | ||||||||
MIRT454344 | CDKL1 | cyclin dependent kinase like 1 | 2 | 2 | ||||||||
MIRT455826 | ZSWIM1 | zinc finger SWIM-type containing 1 | 2 | 3 | ||||||||
MIRT459903 | PIGO | phosphatidylinositol glycan anchor biosynthesis class O | 2 | 12 | ||||||||
MIRT461654 | G6PC | glucose-6-phosphatase catalytic subunit | 2 | 2 | ||||||||
MIRT461934 | TNFSF14 | TNF superfamily member 14 | 2 | 2 | ||||||||
MIRT463834 | WSB1 | WD repeat and SOCS box containing 1 | 2 | 2 | ||||||||
MIRT468615 | SUMO1 | small ubiquitin-like modifier 1 | 2 | 2 | ||||||||
MIRT469456 | REL | REL proto-oncogene, NF-kB subunit | 2 | 6 | ||||||||
MIRT469637 | RAD21 | RAD21 cohesin complex component | 2 | 6 | ||||||||
MIRT473432 | MDM4 | MDM4, p53 regulator | 2 | 2 | ||||||||
MIRT473872 | MAFK | MAF bZIP transcription factor K | 2 | 6 | ||||||||
MIRT476861 | FHL2 | four and a half LIM domains 2 | 2 | 4 | ||||||||
MIRT476893 | FBXO21 | F-box protein 21 | 2 | 2 | ||||||||
MIRT479880 | CCDC43 | coiled-coil domain containing 43 | 2 | 2 | ||||||||
MIRT488848 | UBTF | upstream binding transcription factor, RNA polymerase I | 2 | 2 | ||||||||
MIRT491164 | LRP3 | LDL receptor related protein 3 | 2 | 2 | ||||||||
MIRT497662 | PRMT3 | protein arginine methyltransferase 3 | 2 | 2 | ||||||||
MIRT499314 | ZNF485 | zinc finger protein 485 | 2 | 10 | ||||||||
MIRT499759 | CIRH1A | UTP4, small subunit processome component | 2 | 10 | ||||||||
MIRT500014 | ABCF2 | ATP binding cassette subfamily F member 2 | 2 | 8 | ||||||||
MIRT501090 | SLC7A5 | solute carrier family 7 member 5 | 2 | 4 | ||||||||
MIRT509646 | ZNF354B | zinc finger protein 354B | 2 | 10 | ||||||||
MIRT509945 | TOMM70A | translocase of outer mitochondrial membrane 70 | 2 | 6 | ||||||||
MIRT510320 | SLC2A3 | solute carrier family 2 member 3 | 2 | 4 | ||||||||
MIRT515505 | GTF2F1 | general transcription factor IIF subunit 1 | 2 | 2 | ||||||||
MIRT516410 | COPA | coatomer protein complex subunit alpha | 2 | 2 | ||||||||
MIRT517861 | NCAPD2 | non-SMC condensin I complex subunit D2 | 2 | 4 | ||||||||
MIRT522558 | MCAM | melanoma cell adhesion molecule | 2 | 4 | ||||||||
MIRT523525 | GLUL | glutamate-ammonia ligase | 2 | 2 | ||||||||
MIRT523764 | FBXO27 | F-box protein 27 | 2 | 4 | ||||||||
MIRT524517 | CDK19 | cyclin dependent kinase 19 | 2 | 2 |